Thus, the major benefit from radical cure with PMQ (in the higher doses necessary in SE Asia) in preventing recurrent malaria and attenuating any associated anemia is offset by the risk to G6PD-heterozygous females diagnosed as “G6PD normal” with current tests who may still have clinically significant oxidant hemolysis [24, 25]. This evidence concerns the gene G6PD and anemia (phenotype).